Genvor Inc (GNVR) director converts accrued payables into 524,000 shares

Rhea-AI Filing Summary

Genvor Inc. reported that Dr. Jesse Jaynes, a director and Chief Research Officer, acquired common stock through conversions of accrued payables owed to him. On 05/08/2025, Dr. Jaynes received 400,000 shares of common stock at $0.25 per share through the conversion of $100,000 in accrued payables. On 12/02/2025, he received an additional 124,000 shares at $1.50 per share by converting $186,000 in accrued payables. After these transactions, Dr. Jaynes directly beneficially owned 524,000 shares of Genvor Inc. common stock.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jaynes Jessee M

(Last) (First) (Middle)

1550 W HORIZON RIDGE PKWY

STE R #3040

(Street)

HENDERSON NV 89012

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Genvor Inc [ GNVR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Research Officer

3. Date of Earliest Transaction (Month/Day/Year)
05/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	05/08/2025		A		400,000	A	$0.25(1)	400,000	D
Common Stock	12/02/2025		A		124,000	A	$1.5(2)	524,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Conversion of $100,000 in accrued payables due to Dr. Jaynes at $0.25/share.

2. Conversion of $186,000 in accrued payables due to Dr. Jaynes at $1.50/share.

	/s/ Dr. Jesse Jaynes	12/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Genvor Inc (GNVR) disclose for Dr. Jesse Jaynes?

The filing shows that Dr. Jesse Jaynes, a director and Chief Research Officer of Genvor Inc., acquired common stock by converting accrued payables owed to him into shares on two separate dates in 2025.

How many Genvor Inc (GNVR) shares did Dr. Jesse Jaynes acquire and at what prices?

Dr. Jaynes acquired 400,000 Genvor common shares at $0.25 per share on 05/08/2025, and 124,000 shares at $1.50 per share on 12/02/2025.

What amounts of accrued payables to Dr. Jesse Jaynes were converted into Genvor Inc (GNVR) stock?

The transactions converted accrued payables of $100,000 at $0.25 per share and $186,000 at $1.50 per share into Genvor Inc. common stock owed to Dr. Jaynes.

What is Dr. Jesse Jaynes' role and relationship to Genvor Inc (GNVR)?

Dr. Jesse Jaynes is disclosed as a Director and an Officer of Genvor Inc., serving as Chief Research Officer, and is a reporting person for these insider transactions.

How many Genvor Inc (GNVR) shares does Dr. Jesse Jaynes beneficially own after the reported transactions?

Following the reported acquisitions, Dr. Jaynes beneficially owns 524,000 shares of Genvor Inc. common stock, held with direct ownership.

Were the reported Genvor Inc (GNVR) insider transactions in cash or via conversion?

Both transactions were described as conversions of accrued payables owed to Dr. Jaynes into Genvor Inc. common stock, rather than open-market cash purchases.